Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001

International Journal of Epidemiology

Volumn 32, Issue 5, 2003, Pages 717-724

  Law, Matthew G ^a   Dore, Gregory J ^a   Bath, Nicky ^b   Thompson, Sandra ^c   Crofts, Nick ^d   Dolan, Kate ^e   Giles, Wendy ^f   Gow, Paul ^g   Kaldor, John ^a   Loveday, Stuart ^h   Powell, Elizabeth ⁱ   Spencer, Jenean ^j   Wodak, Alex ^k  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Australian Injecting and Illicit Drug Users' League (AIVL)   (Australia)

^c DEPARTMENT OF HEALTH   (Australia)

^d MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f Austin Repatriation Medical Centre ^*  (Australia)

^g AUSTIN HEALTH   (Australia)

^h Australian Hepatitis Council   (Australia)

ⁱ PRINCESS ALEXANDRA HOSPITAL   (Australia)

^j St Vincent's Hospital ^*  (Australia)

^k ST VINCENT S HOSPITAL   (Australia)

more..

Author keywords

Australia; Drug abuse; Epidemiology; Hepatitis C; Models

Indexed keywords

HEPATITIS C ANTIBODY;

DISEASE PREVALENCE; HEPATITIS; MEDICAL GEOGRAPHY; METHODOLOGY; MODELING;

ACCURACY; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DISEASE TRANSMISSION; DRUG ABUSE; EPIDEMIC; HEALTH CARE PLANNING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR;

AUSTRALIA; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; MODELS, STATISTICAL; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE ABUSE, INTRAVENOUS;

AUSTRALIA;

EID: 0142154387     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/dyg101     Document Type: Article

References (30)

1. Commonwealth Department of Health and Ageing. National Notifiable Diseases Surveillance System, 2002. (available at http://www.health.gov.au/pubhlth/cdi).
2. Dore GJ, Pritchard-Jones J, Fisher D, Law MG. Who's at risk? Risk factors for HCV infection in Australia. Australian Family Physician 1999;28(Special Issue):S18-S113.
3. Crofts N, Jolley D, Kaldor J, van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drugs users in Australia. J Epidemiol Community Health 1997;6:692-97.
4. Law MG on behalf of the Hepatitis C Virus Projections Working Group. Modelling the hepatitis C virus epidemic in Australia. J Gastroenterol Hepatol 1999;14:1100-07.
5. Commonwealth Department of Health and Human Services. National Drug Strategy Household Survey: Survey Report 1995. Canberra, Australian Government Printing Service, 1996.
6. Australian Institute of Health and Welfare. 1998 National Drug Strategy Household Survey: First Results. AIHW cat. No. PHE 15. Canberra: AIHW (Drug Statistics Series), 1999.
7. Hall W, Ross JE, Lynskey MT, Law MG, Degenhardt LJ. How many dependent heroin users are there in Australia? Med J Aust 2000;173:528-31.
8. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, Hepatitis C and Sexually Transmissible Infections in Australia: Annual Surveillance Report 2001. NCHECR (Ed), Sydney, 2001. (available at http://www.med.unsw.edu.au/nchecr.)
9. Thorley A. Longitudinal studies of drug dependence. In: Edwards G, Busch C (eds). Drug Problems in Britain: A Review of Ten Years. London: Academic Press, 1981.
10. English D, Holman CDJ, Milne E et al. The Quantification of Drug Caused Morbidity and Mortality in Australia. Canberra: Commonwealth Department of Human Services and Health, 1995.
11. van der Poel CL, Cuypers, HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994;334:1475-79.
12. Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ 1997;315:333-37.
13. Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16.
14. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatology 2001;34:730-39.
15. Australian Bureau of Statistics. Deaths, Australia 1994. ABS Catalogue No. 3302.0. AGPS, Canberra, 1995.
16. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
17. Bennett WG, Inoue Y, Beck JR et al. Estimates of the cost-effectiveness of a single course of interferon- alpha2B in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
18. Bonkovsky HL, Woolley JM, and the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264-70.
19. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999;30:1299-301.
20. Rouen D, Dolan K, Day C, Topp L, Darke S, Hall W. Changes in Heroin Availability in Sydney, Australia in Early 2001. NDARC Technical Report No. 119, UNSW, Sydney, 2001.
21. Degenhardt L. Opioid Overdose Deaths in Australia. Sydney: National Drug and Alcohol Research Centre, 2001.
22. Garner JF, Gaughwin M, Dodding J, Willson K. Prevalence of hepatitis C infection in pregnant women in South Australia. Med J Aust 1997;166:470-72.
23. Spencer JD, Tibbits D, Tippet C, Mead C, Kaldor JM, Dore GJ. Review of antenatal testing policies and practice for HIV and hepatitis C infection. Manuscript submitted for publication 2002.
24. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust 2000;173:403-05.
25. Australian Institute of Health and Welfare. Australasian Association of Cancer Registries. Cancer rates in Australia 1998. 2001. (available at http://www/aihw.gov.au).
26. Brotodihardjo AE, Tait N, Weltman MD, Liddle C, Little JM, Farrell GC. Hepatocellular carcinoma in western Sydney: aetiology, changes in incidence, and opportunities for better outcomes. Med J Aust 1994;161:433-35.
27. Thompson SC, Lin A, Warren R, Giles G, Crofts N. Risk factors associated with hepatocellular carcinoma notified to the Anti-Cancer Council of Victoria in 1991-1992. Aust N Z J Public Health 1997;21:626-30.
28. Hall W. The Demand for Methadone Maintenance Treatment in Australia. NDARC Technical Report No. 28, Sydney, 1995.
29. Law MG, Lynskey M, Ross J, Hall W. Back-projection estimates of the number of dependent heroin users in Australia. Addiction 2001;96:433-43.
30. Lynskey M, Degenhardt L, Law MG, Ross J, Hall W. Capture-recapture estimates of the number of individuals who are heroin dependent in New South Wales, Australia. Substance Use and Misuse. In press.